

Product Update

nepafenac 3mg/mL eye drops, suspension (Nevanac[®])

SMC No. (1228/17)

Alcon Eye Care Ltd

10 March 2017

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) and on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

nepafenac (Nevanac[®]) 3mg/mL eye drops are accepted for use within NHS Scotland.

Indication under review: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Nepafenac 3mg/mL eye drops provide a once daily alternative to nepafenac 1mg/mL eye drops (administered three times daily). The cost of a course of treatment is the same for both formulations.

Nepafenac 3mg/mL is also licensed for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery. The company submission related only to reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients. SMC cannot recommend the use of nepafenac eye drops for postoperative pain and inflammation associated with cataract surgery.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 15 February 2017.

Chairman
Scottish Medicines Consortium